Comments
Shares of Dr Reddy’s Laboratories today slumped 10 per cent on reports that USFDA might withhold approval of the company’s fresh drugs and stop import if no corrective action is taken.
The stock plunged 10 per cent to Rs 3,049.75 on the BSE. On the NSE, shares of the company tumbled 8.53 per cent to Rs 3,098.60.
The stock was the worst performer on both the Sensex and the Nifty.
CGMP violations
The regulator said it had found several violations with regard to current good manufacturing practices (CGMP) at three of its plants.
“At Dr Reddy’s Laboratories’ facilities, we identified significant deviations from CGMP for manufacturing of active pharmaceutical ingredients (APIs)... we found significant violations of CGMP regulations for finished pharmaceuticals,” the USFDA noted.
Meanwhile, the BSE has sought clarification from Dr Reddy’s on this issue.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.